Nim­bus found­ing CSO Rosana Kapeller leaves to ex­plore ex­ec role; AI start­up BioX­cel pock­ets $60M from IPO

→ Hav­ing helped turn “the vi­sion of com­pu­ta­tion­al-based drug dis­cov­ery in­to re­al­i­ty”  at Nim­bus Ther­a­peu­tics, found­ing CSO Rosana Kapeller has de­cid­ed it’s time to take on an ex­ec­u­tive lead­er­ship role else­where. Dur­ing her eight-year tenure, the Cam­bridge, MA-based biotech has built up a pipeline span­ning meta­bol­ic, au­toim­mune and im­muno-on­col­o­gy pro­grams. That has at­tract­ed big part­ners and big bucks from Gilead, Genen­tech and Cel­gene. Be­fore join­ing Nim­bus, Kapeller co-found­ed Aileron Ther­a­peu­tics. “Rosana is a top-notch sci­en­tist who is uni­form­ly ad­mired by the team at Nim­bus and our wide ar­ray of cor­po­rate and aca­d­e­m­ic part­ners,” Nim­bus CEO Don Nichol­son said in a farewell state­ment. “She has helped as­sem­ble a tal­ent­ed, high cal­iber drug dis­cov­ery or­ga­ni­za­tion which is larg­er and more ca­pa­ble than at any time in our his­to­ry, and the deep ex­pe­ri­ence and tal­ent of our lead­er­ship team has en­abled a seam­less tran­si­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER